The Quantellect read.As of Nov 19, 2026, 9 active firms cover enGene Therapeutics Inc: 3 rate it Buy or better, 5 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $2.00 to $30.00 (about 15.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $10.58 sits 477% above the current $1.83. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Neutral
Strong Buy00%
Buy333%
Neutral556%
Sell111%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$10.58
+476.7% upside
Average target across 6 active firms as of Nov 19, 2026 vs $1.84 current
Highest Target$30.00
Average Target$10.58
Lowest Target$2.00
Detailed analyst forecasts for ENGN
Showing 1–9 of 9 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 3 of 9 active firms rate ENGN a Buy (5 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ENGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.44 – $-0.30 · 3 analysts · -14% YoY
Next period, 3 analysts expect enGene Therapeutics Inc. to earn $-0.38 a share (range $-0.44 – $-0.30), versus $-0.44 a year earlier. Full-year consensus is $-1.82, growing to $-1.59 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0)., rising to $4.7M next year.
Top analysts covering enGene Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENGN.
#1
Michael Schmidt
Guggenheim · Rank #4
Neutral
No targeton ENGN
Overall win rate
53%
+ Follow
#2
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Buy
$19.00+935.4% to target
Overall win rate
64%
+ Follow
#3
Silvan Tuerkcan
JMP Securities · Rank #69
Neutral
No targeton ENGN
Overall win rate
51%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$4.00+118.0% to target
Overall win rate
39%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #404
Neutral
No targeton ENGN
Overall win rate
35%
+ Follow
ENGN stock forecast FAQ
What is ENGN's average 12-month price target?+
The 6 active firms with a live target average $10.58 for enGene Therapeutics Inc. over the next 12 months, ranging from a $30.00 high to a $2.00 low, as of Nov 19, 2026.
Is ENGN stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 9 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 5 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ENGN?+
The Street-high target is $30.00 (Oppenheimer), and the Street-low is $2.00 (UBS). The average of all 6 active-firm targets is $10.58.
How many active Wall Street firms cover ENGN?+
9 active firms have a recognized rating on enGene Therapeutics Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ENGN?+
Among analysts who currently cover ENGN, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Neutral.
What is enGene Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.44 – $-0.30) across 3 analysts. Full-year EPS is projected at $-1.82, rising to $-1.59 the following year.
How much revenue is enGene Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at —, growing to $4.7M next year.
Have analysts been upgrading or downgrading ENGN lately?+
As of Nov 19, 2026, 3 of 9 active firms rate ENGN a Buy (5 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.